Library — CHDR

Search

Filter

Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men.

Khalili-Mahani N, Niesters M, van Osch MJ, Oitzl M, Veer I, de Rooij M, van Gerven J, van Buchem MA, Beckmann CF, Rombouts SA, Dahan A

NeuroImage, 2015 Feb

View publication
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, van Gerven JM, Cohen AF, Freijer J

Clinical pharmacokinetics, 2015 Jan; 54(2):209-19

View publication
The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol.

Kleinloog D, Stevens J, Heuberger J, Spinhoven P, van Gerven J

Psychiatry research, 2014 Dec; 220(3):945-53

View publication
The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Chen X, Jacobs G, de Kam M, Jaeger J, Lappalainen J, Maruff P, Smith MA, Cross AJ, Cohen A, van Gerven J

British journal of clinical pharmacology, 2014 Nov; 78(6):1298-314

View publication
Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.

Hoch M, van Gorsel H, van Gerven J, Dingemanse J

Journal of clinical pharmacology, 2014 Aug; 54(9):979-86

View publication
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.

Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014 Jul; 24(8):1257-68

View publication
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.

Klumpers LE, Roy C, Ferron G, Turpault S, Poitiers F, Pinquier JL, van Hasselt JG, Zuurman L, Erwich FA, van Gerven JM

British journal of clinical pharmacology, 2013 Jun; 76(1):65-77

View publication
Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.

Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, de Kam ML, Franson KL, Cohen AF, van Gerven JM

British journal of clinical pharmacology, 2013 May; 75(6):1455-67

View publication
Determination of methylphenidate in plasma and saliva by liquid chromatography/tandem mass spectrometry.

Seçilir A, Schrier L, Bijleveld YA, Toersche JH, Jorjani S, Burggraaf J, van Gerven J, Mathôt RA

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013 Mar

View publication

«
1
2
3
4
5
6
7
8
...
13
14
»